Future studies are warranted for breast cancer patients who receive (neo)adjuvant anti-HER2 therapy to determine the prognostic and potentially predictive utility of the HER2 ITH and ITH evaluation method developed here. The gene discussed is ERBB2; the disease is breast cancer.